Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus gasseri BNR17
- Development stage
- Unknown
- Lead developer
- AceBiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus gasseri BNR17 is a specific probiotic strain of the species *Lactobacillus gasseri*, originally isolated from human breast milk. It is used as a dietary supplement and live biotherapeutic product, primarily for its potential benefits in metabolic health, including anti-obesity effects and improvement of gut health. Preclinical studies have shown that administration of L. gasseri BNR17 can reduce body weight gain, adipose tissue mass, and serum leptin/insulin levels in animal models by upregulating fatty acid oxidation genes (ACO, CPT1, PPARα, PPARδ) and downregulating fatty acid synthesis genes (SREBP-1c, ACC). Clinical trials in overweight or obese adults have demonstrated reductions in visceral fat area and waist circumference after supplementation with this strain for 12 weeks[2][5][6]. Additionally, randomized controlled trials suggest it may improve symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D), including abdominal pain and stool frequency[8]. The mechanism involves modulation of host metabolism via changes to the gut microbiota composition and enhancement of intestinal barrier function.
- Brand names
- Acebiome BNR17 Diet Probiotics BNRThin ProDr. Mercola Biothin Probiotic Lactobacillus Gasseri
- Other names
- L. gasseri BNR17Lactobacillus gasseri strain BNR17
Beyond the preview
Go deeper on Lactobacillus gasseri BNR17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus gasseri BNR17.